Aktuelle Rheumatologie 2015; 40(01): 77-80
DOI: 10.1055/s-0034-1398519
Übersichtsarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Systemischer Lupus erythematodes –die Standards 2015 [*]

Systemic lupus erythematosus – Standards in 2015
M. Aringer
1   Rheumatologie, Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus, TU Dresden
,
M. Schneider
2   Poliklinik für Rheumatologie, Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

eingereicht 21 May 2014

akzeptiert 23 July 2014

Publication Date:
17 February 2015 (online)

* Dieser Beitrag ist zuerst erschienen in Dtsch Med Wochenschr 2014; 139: 1813–1816.


 
  • Literatur

  • 1 Agmon-Levin N, Damoiseaux J, Kallenberg C et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014; 73: 17-23
  • 2 Aringer M, Burkhardt H, Burmester GR et al. Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland – a consensus report. Lupus 2012; 21: 386-401
  • 3 Aringer M, Fischer-Betz R, Hiepe F. Statement on the use of mycophenolate mofetil for systemic lupus erythematosus. Z Rheumatol 2013; 72: 575-580
  • 4 Aringer M, Schneider M. Recipes systemic lupus erythematosus. Z Rheumatol 2014;
  • 5 Arnaud L, Mathian A, Ruffatti A et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014; 13: 281-291
  • 6 Bauernfeind B, Aringer M, Prodinger B et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum 2009; 61: 21-28
  • 7 Bertsias GK, Ioannidis JP, Aringer M et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-2082
  • 8 Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782
  • 9 Fischer-Betz R, Schneider M. Recommendation for use of belimumab for systemic lupus erythematosus. Z Rheumatol 2013; 72: 462-467
  • 10 Fischer-Betz R, Spathling-Mestekemper S. Pregnancy and inflammatory rheumatic diseases. Z Rheumatol 2013; 72: 669-682
  • 11 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725
  • 12 Mosca M, Tani C, Aringer M et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-1274
  • 13 Specker C. Antiphospholipid-Syndrom – wann behandeln?. Dtsch Med Wochenschr 2012; 137: 1748-1750
  • 14 Strand V, Levy RA, Cervera R et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014; 73: 838-844
  • 15 van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014; 73: 958-967